Sign In
Buy BPTH
$0.0300
+0.0066 (+28.21%)
At Close: Jun 03, 2026
Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock
07:15am, Tuesday, 16'th Feb 2021
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
07:00am, Saturday, 13'th Feb 2021
HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop
Why Bio-Path's Stock Is Surging Higher Today
02:01pm, Wednesday, 10'th Feb 2021
Bio-Path (NASDAQ: BPTH) shares are trading higher Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology. Bio-Path Holdings I
BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today
12:29pm, Wednesday, 10'th Feb 2021
Bio-Path Holdings (BPTH) stock is rocketing higher on Wednesday after announcing patent updates for its DNAbilize platform. The post BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today appear
BPTH Stock Price Increases Over 80% Pre-Market: Why It Happened
08:48am, Wednesday, 10'th Feb 2021
The stock price of Bio-Path Holdings Inc (NASDAQ: BPTH) is trading at over 80% pre-market. This is why it happened.
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology
07:00am, Wednesday, 10'th Feb 2021
Provides Expanded Protection to Seminal Patents Related to DNAbilize Provides Expanded Protection to Seminal Patents Related to DNAbilize
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
07:00am, Thursday, 19'th Nov 2020
Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Prote
Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q3 2020 Results - Earnings Call Transcript
12:53pm, Friday, 13'th Nov 2020
Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q3 2020 Results - Earnings Call Transcript
Bio-Path Holdings Reports Third Quarter 2020 Financial Results
07:00am, Friday, 13'th Nov 2020
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
08:00am, Friday, 06'th Nov 2020
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p
Mid-Afternoon Market Update: Dow Jumps 200 Points; Align Technology Shares Climb After Q3 Results
12:00am, Thursday, 22'nd Oct 2020
Toward the end of trading Thursday, the Dow traded up 0.71% to 28,411.36 while the NASDAQ rose 0.29% to 11,518.30. The S&P also rose, gaining 0.61% to 3,456.52.
The U.S. has...
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%
12:00am, Friday, 21'st Aug 2020
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%
Bio-Path Holdings Inc (BPTH) CEO Peter Nielsen on Q2 2020 Results - Earnings Call Transcript
11:56am, Friday, 14'th Aug 2020
Bio-Path Holdings Inc (NASDAQ:BPTH) Q2 2020 Results Conference Call August 14, 2020 08:30 AM ET Company Participants Will O’Connor - Stern Investor Relations Peter Nielsen - President, Chief Executi
Bio-Path Holdings Reports Second Quarter 2020 Financial Results
11:00am, Friday, 14'th Aug 2020
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ lipos
Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several Potential Pathways to RegistrationHOUSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),
